Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.SunLink Health Systems, Inc. (NYSE:SSY) announced earnings from continuing operations for its fiscal quarter ended September 30, 2009 of $549,000, or $0.07 per fully diluted share, compared to a loss from continuing operations of $603,000, or $0.08 per fully diluted share, for the quarter ended September 30, 2008.Enzo Biochem Inc. (NYSE:ENZ) announced today that David Goldberg, Vice President, Corporate Development, will speak on the Company’s extensive oral immune regulation platform at the Windhover TA Partnerships 2009 conference in Boston, MA, on Wednesday, November 18, 2009, where Enzo’s EGS21, an orally administered beta glucosylceramide formulation, now undergoing clinical study, was named one of this year’s “top 10 inflammatory/autoimmune projects to watch.”Pro-Pharmaceuticals, Inc. (OTCBB: PRWP), a developer of galectin-targeted, carbohydrate therapeutic compounds to treat cancer and fibrosis, today reported its financial results for the third quarter and first nine months of fiscal 2009.Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to treat chronic and acute wounds, today announced that its development partners, Bayer Animal Health divisions in China and Taiwan, recently secured regulatory approvals in both those countries to develop and market Microcyn-based Vetericyn™ products for their respective animal healthcare markets.Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, announced today that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference in New York City.Ore Pharmaceutical Holdings Inc. (NASDAQ:ORXE) today reported financial results and provided an operational update for the third quarter ended September 30, 2009.China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics," "the Company"), a leading Chinese firm specializing in the research, development, manufacture, marketing and distribution of probiotics dietary supplements, today announced it will host a conference call at 11:00 a.m. EST on Tuesday, November 17, 2009, to discuss the Company's financial results for the second quarter of its 2010 fiscal year.NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a clinical-stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections, today reported financial results for the third quarter ended September 30, 2009.Exelixis, Inc. (Nasdaq:EXEL) announced today that Frank Karbe, the company’s executive vice president and chief financial officer, will present at Lazard’s 6th Annual Healthcare Conference at 11:00 a.m. EST / 8:00 a.m. PST on Wednesday, November 18, 2009 in New York.Columbia Laboratories, Inc. (Nasdaq: CBRX) today commented that nothing fundamental in the Company’s operations has changed to cause the current market activity in its Common Stock.Talecris Biotherapeutics (Nasdaq: TLCR) and N.C. Gov. Bev Perdue jointly announced today that the company will expand its manufacturing facilities in Clayton, creating 259 new jobs over the next seven years.PanGenex Corporation (Pink Sheets:PGCX), a global nutraceutical and dietary supplement manufacturer and marketer, is pleased to announce today that two of the nation's leading interventional cardiologists, Dr. Steven Yakubov and Dr. Mark Turco, have joined the Company's Scientific Advisory Board.Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 1:40 p.m. ET will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com.Genzyme Corp. (Nasdaq:GENZ) announced today that it has issued letters to U.S. healthcare providers regarding its enzyme replacement products Cerezyme® (miglucerase for injection), Fabrazyme® (agalsidase beta), Myozyme® (alglucosidase alfa), Aldurazyme® (laronidase), as well as Thyrogen® (thyrotropin alfa for injection), filled at its Allston Landing manufacturing facility.King Pharmaceuticals, Inc. (NYSE:KG) today announced plans to present at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, 2009, at 2:15 pm EST, at the St. Regis Hotel in New York, New York.MedaSorb Technologies Corporation (OTCBB:MSBT) and its wholly-owned subsidiary, CytoSorbents, Inc., today announced the filing of Q3 2009 financial results as reported in its Form 10-Q with the SEC.

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

Biovail Corporation (NYSE:BVF) announced it will host a conference call and webcast on Thursday, November 5, 2009 at 8:30a.m. for Company executives to discuss third-quarter 2009 financial and operational results.

avVaa World Health Care Products Inc. (OTC:AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeuticnatural skin and health care products, announced their third Direct TV Media Test is scheduled to launch on Thursday October 29.Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced Fred W. Driscoll, VP and CFO, will be presenting at the 8th Annual BIO Investor Forum 2009 at 11:00 am local time on October 29, 2009 at the Palace Hotel in San Francisco, California.

Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 Allergan, Inc. (NYSE:AGN) announced the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc.Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.Columbia Laboratories, Inc. (Nasdaq:CBRX) announced it has priced a transaction to raise up to approximately $11,772,000 through the sale of up to approximately 10,900,000 shares of its common stock and warrants to purchase 5,450,000 shares of its common stock in a registered direct offering.Biovail Corporation (NYSE:BVF) announced it will host a conference call and webcast on Thursday, November 5, 2009 at 8:30a.m. for Company executives to discuss third-quarter 2009 financial and operational results. Lightlake Therapeutics Inc. (OTC:LLTP), a drug discovery company developing innovative solutions to combat the worldwide epidemic in obesity – a trillion dollar market - has appointed Dr Roger Crystal as CEO. Ferro Corporation (NYSE:FOE) announced it will conduct a conference call on Tuesday, October 27, at 10:00 a.m. Eastern Time to discuss financial results for the three months ended September 30, 2009 and factors which are expected to affect the Company's future performance.Mediware Information Systems, Inc. (NASDAQ:MEDW) announced the Blood Bank of Alaska is the latest major blood center to license LifeTrak®, the company's 510(k) cleared blood donor management software. Inhibitex, Inc. (Nasdaq:INHX) announced it has entered into definitive purchase agreements with institutional investors for the sale of approximately $23 million of its common stock, and warrants to purchase common stock, in a private placement.Advaxis, Inc., (OTC:ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, has announced the appointment of Christopher Duignan to the role of senior vice president, Finance, working alongside Advaxis CFO Fredrick Cobb, effective immediately.

Lpath, Inc. (OTC:LPTN), the category leader in therapeutic agents against bioactive lipids, will present at the 2009 BIOCOM Investor Conference, which will be held October 26-27, 2009 at the Hyatt Regency La Jolla in San Diego, California.Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced it will report its financial results for the quarter ended September 30, 2009, on Wednesday, November 4, 2009.Orthovita, Inc. (NASDAQ:VITA), an orthobiologics and biosurgery company, is pleased to announce Dr. Pierce D. Nunley, Director of the Spine Institute of Louisiana, will present his abstract, “A Comparison of Clinical Outcomes and Adjacent Level Fractures in Patients Receiving Vertebroplasty for Osteoporotic Compression Fractures Using CortossTM or PMMA: A Prospective, Randomized Trial,” at the 2009 Annual Meeting of the Congress of Neurological Surgeons (CNS).Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI), announced the commercial launch of the Tan EndoGlide(TM) Endothelium Insertion System in the United States.Unilife Medical Solutions Limited (OTC:UNIFF) announced its Chief Executive Officer Alan Shortall has made open market purchases of Company shares.Senetek PLC (OTC:SNKTY), a Life Sciences company engaged in the research, development and commercialization of technologies which target the science of healthy aging, announced it has engaged Miller Tabak + Co., LLC as exclusive financial advisor to assist the Board of Directors with a review of strategic options and development of a business plan to maximize the assets of the company.Escalon Medical Corp. (Nasdaq:ESMC) announced its Sonomed, Inc. subsidiary's introduction of the new PacScan(TM) Plus, an A-Scan with optional pachymeter.

Kensey Nash Corp. (KNSY) recently reported strong results for the fourth quarter and full year 2009. Quarterly profit came in at 41 cents per share, compared to the Zacks Consensus Estimate of 38 cents and the year-ago loss of 9 cents per share. Quarterly Results Sales Net sales in the quarter were $20.5 million, down about 7% [...]

(KNSY) Kensey Beats Consensus Estimate

The indices had another strong start to the week with another strong gap up at the opening on very positive futures.  They then backed and filled, retested early lows and then rallied steadily to mid-afternoon when they reached their peaks for the day.  They pulled back into the last hour, but in the last 15-mintues snapped back sharply to close near the highs for the day on the Nasdaq 100 and not far from them on the S&P 500. Net on the day the Dow gained 114.95 to 9286.56, just 12 points off its high.  The S&P 500 was up 15.15 to 1002.63, closing over 1000 for the first time since November.  That was less than a point from its highs.  The Nasdaq 100 advanced 24.76 to 1628.12, just pennies from its high. Advance-declines were 5 to 1 positive on New York and 2/1/2 to 1 positive on Nasdaq.   Up/down volume was about 7 1/2 to 1 positive on New York on total volume of just under 1.2[More...]

We had another up-day, and the indices started with a big rally that broke key multiple session consolidation ranges and went to new 3-week & 2009 rally highs. The rally in the morning took the Nasdaq 100 to a new rally high at nearly 1633, the highest level reached since early November of last year.  The S&P 500 reached 996.68, the highest level since late September of last year.  They pulled back late in the morning and then consolidated mid-day, but when no rally materialized late in the session they rolled over hard and took back a big chunk of the gains. Net on the day the Dow was up 86.74 to 9154.46, but traded nearly 90 points higher earlier in the day.  The S&P 500 was up 11.60 to 986.75, about 10 points off the high, and the Nasdaq 100 closed up 10.26 at 1601.97, but gave back 22 points off its high. Advance-declines were positive by 4 to 1 on New York and 2 12 to 1 on[More...]